Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Moderna (MRNA)

NASDAQ: MRNA · Biotechnology · Cambridge, MA

Our rating: Cautious

Cautious reaffirmed at $269.00, high conviction, November 9, 2026.

Breaks if: The cautious call would need revisiting if Moderna's trailing twelve-month revenue reaches $4 billion or above within the next four quarterly filings — roughly double the current run-rate — alongside a narrowing of free cash flow burn to better than negative $800 million, together signaling a credible floor in the revenue decline and a cost structure beginning to right-size. If the stock sustains a price above $350 for more than thirty consecutive trading days without a corresponding improvement in those fundamentals, that would equally signal the market is pricing in catalysts not yet visible in the filings.

Key figures

Market value$78.9B
Revenue, last 12 months$2.5B
Net income, last 12 months−$2.8B
Free cash flow, last 12 months−$2.0B
Price to earningsn/a
Free cash flow yield−2.5%
Dividend yield0.0%
Operating margin−116.0%
Return on equity−34.5%
Beta to the S&P 5001.52
Volatility, annualized133.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.3B29.2%$0.38−$1.6B
June 30, 2026$145M2.1%$-1.97−$563M
March 31, 2026$389M260.2%$-3.40−$692M
December 31, 2025$678M−29.8%$-2.11$891M
September 30, 2025$1.0B−45.4%$-0.51−$880M
June 30, 2025$142M−41.1%$-2.13−$922M
March 31, 2025$108M−35.3%$-2.52−$1.2B
December 31, 2024$966M−65.6%$-2.91$303M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

57 ledger entries and 14 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.